Hélène E Aschmann

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Clinical trials (London, England)

JMIR public health and surveillance

Proceedings of the National Academy of Sciences of the United States of America

Multiple sclerosis journal - experimental, translational and clinical

University of Zurich (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Zurich Apr 01 2016

Switzerland

PHD :: Epidemiology, Biostatistics and Prevention Institute

Swiss Federal Institute of Technology in Zurich

Switzerland

MSC :: Pharmaceutical Sciences

Publications

Hélène E Aschmann, Allan Musinguzi, Jillian L Kadota, Catherine Namale, Juliet Kakeeto, Jane Nakimuli, Lydia Akello, Fred Welishe, Anne Nakitende, Christopher Berger, David W Dowdy, Adithya Cattamanchi, Fred C Semitala, Andrew D Kerkhoff
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens - a discrete choice experiment. medRxiv : the preprint server for health sciences (2023)
Hélène E Aschmann, Alicia R Riley, Ruijia Chen, Yea-Hung Chen, Kirsten Bibbins, Andrew C Stokes, M Maria Glymour, Mathew V Kiang
Dynamics of racial disparities in all-cause mortality during the COVID-19 pandemic. Proceedings of the National Academy of Sciences of the United States of America 119 (40) (2022)
Yea-Hung Chen, Andrew C Stokes, Hélène E Aschmann, Ruijia Chen, Shelley DeVost, Mathew V Kiang, Suneil Koliwad, Alicia R Riley, M Maria Glymour, Kirsten Bibbins
Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021. PNAS nexus 1 (3) (2022)
Alessandra Spanu, Hélène E Aschmann, Jürg Kesselring, Milo A Puhan
Fingolimod versus interferon beta 1-a: Benefit-harm assessment approach based on TRANSFORMS individual patient data. Multiple sclerosis journal - experimental, translational and clinical 8 (3) (2022)
Hélène E Aschmann, John J McNeil, Milo A Puhan
Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit-harm balance. Clinical trials (London, England) 19 (2) (2022)
Hélène E Aschmann, John J McNeil, Milo A Puhan
Rejoinder to Dr Vickers. Clinical trials (London, England) 19 (2) (2022)
Tala Ballouz, Dominik Menges, Hélène E Aschmann, Ruedi Jung, Anja Domenghino, Jan S Fehr, Milo Alan Puhan, Viktor Von Wyl
Individual-Level Evaluation of the Exposure Notification Cascade in the SwissCovid Digital Proximity Tracing App: Observational Study. JMIR public health and surveillance 8 (5) (2022)
Dominik Menges, Tala Ballouz, Alexia Anagnostopoulos, Hélène E Aschmann, Anja Domenghino, Jan S Fehr, Milo Alan Puhan
Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PloS one 16 (7) (2021)
Hélène E Aschmann, Cynthia M Boyd, Craig W Robbins, Richard A Mularski, Wiley V Chan, Orla C Sheehan, Renée F Wilson, Wendy L Bennett, Elizabeth A Bayliss, Tsung Yu, Bruce Leff, Karen Armacost, Carol Glover, Katie Maslow, Suzanne Mintz, Milo A Puhan
Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment. BMJ open 9 (8) (2019)

Hélène E Aschmann.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hélène E Aschmann